PhaseBio Pharmaceuticals Inc. (PHAS) Announces CFO Resignation
- Wall Street mixed; Dow pressured by selloff in Salesforce shares
- S&P 500 to re-test lows in H1 and then rally to 4200 on Fed pivot signal - JPMorgan
- Salesforce (CRM) drops after soft results, MS sees attractive valuation
- Snowflake (SNOW) falls as macro headwinds drag on guidance, analysts remain upbeat
- Piper Sandler says Apple (AAPL) likely lost 9M iPhone 14 units, cuts revenue estimates
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
On November 21, 2022, John P. Sharp, Chief Financial Officer of PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS), informed the Company that he was resigning from his position, effective November 30, 2022, to pursue another employment opportunity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spark Networks SE (LOV) Names Board Vice Chair Chelsea A. Grayson As Interim CEO
- Digimarc Corporation (DMRC) Expands Partnership with Walmart in a New Multiyear Agreement
- Viveve Medical (VIVE) Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
Create E-mail Alert Related CategoriesCorporate News, Management Changes
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!